CRC Research Update — August 13, 2026
Today's colorectal cancer research highlights
Archive
A collection of 715 issues
Latest
Serbian cohort reveals MLH1 as predominant Lynch syndrome variant
Skip to content
The CRC Digest
Serbian cohort reveals MLH1 as predominant Lynch syndrome variant
Germline testing of 176 high-risk individuals in Serbia identified pathogenic variants predominantly in MLH1, highlighting the need for population-specific genetic testing strategies in hereditary colorectal cancer screening. (Int J Mol Sci)
This content is informational
Co-mutations in CREBBP/EP300 and POLE/POLD1 identify high tumor mutational burden in MSS colorectal cancer
Skip to content
The CRC Digest
Co-mutations in CREBBP/EP300 and POLE/POLD1 identify high tumor mutational burden in MSS colorectal cancer
Analysis of over 30,000 tumors found that co-mutation of CREBBP/EP300 and POLE/POLD1 strongly predicted elevated tumor mutational burden in microsatellite-stable disease (median 155.9 vs.
Phase III trial launches to prevent oxaliplatin-induced neuropathy in adjuvant treatment
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Phase III trial launches to prevent oxaliplatin-induced neuropathy in adjuvant treatment
The PROSPER trial will test lecithinized superoxide dismutase (PC-SOD) against placebo to prevent chemotherapy-induced peripheral neuropathy in stage II/III colorectal cancer patients receiving adjuvant mFOLFOX6, following promising phase II
Dual immunotherapy may outperform single-agent pembrolizumab in MSI-H metastatic colorectal cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Dual immunotherapy may outperform single-agent pembrolizumab in MSI-H metastatic colorectal cancer
An indirect comparison using reconstructed patient data from KEYNOTE-177 and CheckMate 8HW suggests nivolumab-ipilimumab may offer progression-free survival benefits over pembrolizumab in first-line MSI-H/dMMR metastatic disease, though grade 3/4
Inflammation may limit muscle-building benefits of high-protein nutrition during treatment
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Inflammation may limit muscle-building benefits of high-protein nutrition during treatment
A post-hoc analysis of the PRIMe trial found that baseline systemic inflammation influenced the effectiveness of high-protein nutritional support to increase lean soft tissue in patients with stage II-IV colorectal cancer.
TAP1 deficiency creates new immunotherapy targets in colorectal cancer
Skip to content
The CRC Digest
◇ RESEARCH
TAP1 deficiency creates new immunotherapy targets in colorectal cancer
Loss of TAP1, an immune escape mechanism found in 26% of colorectal cancers, generates alternative T cell epitopes that may be exploitable for immunotherapy; researchers identified CD8 T cells from patient tumors that can
Targeting peripheral serotonin receptor enhances antitumor immunity in colorectal cancer
Skip to content
The CRC Digest
◇ RESEARCH
Targeting peripheral serotonin receptor enhances antitumor immunity in colorectal cancer
Researchers developed IHCH-8110, a non-brain-penetrant 5-HT2AR agonist that activates serotonin receptors on enteric glial cells to promote CD8+ T cell recruitment and suppress colorectal cancer growth without psychedelic effects. (Cell)
This content is
AHN researchers help develop blood test that detects colorectal cancer and high-risk polyps
Skip to content
The CRC Digest
▪ SCREENING
AHN researchers help develop blood test that detects colorectal cancer and high-risk polyps
Researchers at Allegheny Health Network contributed to development of a blood-based screening test capable of detecting both colorectal cancer and high-risk polyps. (Beaver County Radio)
This content is informational only
CRC Research Update — August 11, 2026
Today's colorectal cancer research highlights